Spinogenix
Business Services · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1801 Century Park E Ste 2400, Los Angele...Phone Number
(310) 853-5695Website
www.spinogenix.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Spinogenix
Spinogenix is a clinical-stage biopharmaceutical company focused on developing innovative therapies designed to restore and repair synaptic connections in the brain. The companys research centers on addressing neurological, psychiatric, and neurodevelopmental disorders by targeting the underlying loss or dysfunction of synapses rather than only managing symptoms. Through its proprietary platform and investigational small-molecule therapies, Spinogenix aims to promote neuronal function and improve cognitive, behavioral, and motor outcomes across a range of conditions, advancing a regenerative approach to brain health and neurological care.Explore more
Spinogenix Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Spinogenix your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Spinogenix launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Spinogenix is spiking on competitors!
Website visits: Recent activity has been detected on your website
Click to see if Spinogenix had a recent Job posting/layoffs
Check if Spinogenix has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Spinogenix
Funding: Get notified immidiatlly once Spinogenix has new funding data
Earning: See what the market has to say on Spinogenix recently announced quarterly report
Spinogenix, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Spinogenix as Masked Content
Find 3 more new buyers
Compare Similar Companies to Spinogenix
Compare insights from companies similar to Spinogenix, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Spinogenix financials insights
Gather financial insights about Spinogenix, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2026
Private Equity
$10.6M
Spinogenix Tech Stack
A closer look at the technologies used by Spinogenix
Spinogenix News & Media
Spinogenix Receives U.S. FDA Fast Track Designation for Tazbentetol for the Treatment of ALS
Designation Enables an Enhanced Development Path for Tazbentetol and Underscores the Unmet Need for New Treatments In ALS Milestone Follows Recent Announcement of Phase 2a Results Showing Preliminary Evidence that Tazbentetol's First in Class Synaptic Regenerative Mechanism Slowed Rate of...Spinogenix to Present Preclinical Results at ARVO 2026 Demonstrating Neuroprotective Effects of Tazbentetol in Glaucoma and Diabetic Retinopathy Models
New Preclinical Data Show Tazbentetol Reduces Retinal Cell Loss and Preserves Visual Function in Glaucoma and Diabetic Retinopathy Models LOS ANGELES, May 3, 2026 /PRNewswire/ -- Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics designed...Spinogenix Announces CLARITY: a Phase 2b/3 trial of SPG601 for the Treatment of Fragile X Syndrome
LOS ANGELES, April 23, 2026 /PRNewswire/ -- Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics designed to restore synapses to improve the lives of patients, is initiating CLARITY, a Phase 2b/3 adaptive trial evaluating SPG601 in male...New Peer-Reviewed Research Demonstrates Neurophysiological Efficacy of Spinogenix's SPG601 in Patients with Fragile X Syndrome
Study Results, Published in Nature Scientific Reports, Found SPG601 Reduced Signature Changes in High-Frequency Gamma Band Activity and Improved Cognition in FXS Patients LOS ANGELES, April 9, 2026 /PRNewswire/ -- Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering...
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Spinogenix
Sign Up For FreeTo access detailed company insights
Spinogenix is a clinical-stage biopharmaceutical company focused on developing innovative therapies designed to restore and repair synaptic connections in the brain. The companys research centers on addressing neurological, psychiatric, and neurodevelopmental disorders by targeting the underlying loss or dysfunction of synapses rather than only man... Read More
